Screener
Adaptive Biotechnologies ADPT Goodwill
Goodwill at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Long-term marketable securities (amortized cost of $18,908 and $13,220, respectively) | 18,889 | 13,234 |
| Restricted cash | 2,709 | 2,689 |
| Intangible assets, net | 1,307 | 1,726 |
| Goodwill | 118,972 | 118,972 |
| Other assets | 1,237 | 1,207 |
| Total assets | $505,943 | $512,736 |
| Liabilities and shareholders’ equity | ||
| Current liabilities |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's goodwill?
- Adaptive Biotechnologies (ADPT) reported goodwill of $118.97M in Q1 2026.
- How has Adaptive Biotechnologies's goodwill changed year-over-year?
- Adaptive Biotechnologies's goodwill decreased by 0.0% year-over-year, from $118.97M to $118.97M.
- What is the long-term trend for Adaptive Biotechnologies's goodwill?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $118.97M to $118.97M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Adaptive Biotechnologies's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude